Article

Lawmakers Hear Evidence of Gray Market in Shortage Drugs

An investigation by congressional staff concluded that so-called gray market companies were identifying weak points in the drug distribution system and taking steps to drive up prices for drugs that were determined to be in short supply.

These companies are profiteers that zero in on short-supply drugs and sell them at inflated prices, said Sen. Jay Rockefeller (D, W.Va.), chair of the Senate Committee on Commerce, Science and Transportation. During a July 25 committee hearing, Rockefeller unveiled the findings of a price-gouging investigation in which his office collaborated with the staffs of Sen. Tom Harkin (D, Iowa) and Rep. Elijah Cummings (D, Md.).

Read the full story: http://tinyurl.com/9tzy3mn

Source: amednews.com

Related Videos
John Barkett, MBA
John Barkett, MBA
John Barkett, MBA
Tom Belmont
Dr Mingyang Song
John Michael O'Brien, PharmD, MPH
Dr Kimlin Tam Ashing
H. John Beardsley, MBA, and Fauzea Hussain, MPH, sitting for a video interview
Dr Kimlin Tam Ashing
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo